A detailed history of Creative Planning transactions in Genmab A/S stock. As of the latest transaction made, Creative Planning holds 47,422 shares of GMAB stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,422
Previous 20,069 136.29%
Holding current value
$1.02 Million
Previous $504,000 129.37%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$23.84 - $28.48 $652,095 - $779,013
27,353 Added 136.29%
47,422 $1.16 Million
Q2 2024

Aug 15, 2024

SELL
$25.13 - $30.27 $421,203 - $507,355
-16,761 Reduced 45.51%
20,069 $504,000
Q1 2024

May 10, 2024

BUY
$26.43 - $32.77 $372,345 - $461,663
14,088 Added 61.95%
36,830 $1.1 Million
Q4 2023

Feb 14, 2024

SELL
$27.94 - $35.44 $96,029 - $121,807
-3,437 Reduced 13.13%
22,742 $724,000
Q3 2023

Nov 16, 2023

BUY
$35.27 - $42.24 $221,530 - $265,309
6,281 Added 31.57%
26,179 $923,000
Q2 2023

Jul 21, 2023

BUY
$37.4 - $42.94 $111,938 - $128,519
2,993 Added 17.7%
19,898 $756,000
Q1 2023

May 15, 2023

BUY
$34.88 - $43.22 $65,155 - $80,734
1,868 Added 12.42%
16,905 $638,000
Q4 2022

Feb 10, 2023

BUY
$33.8 - $47.06 $92,375 - $128,614
2,733 Added 22.21%
15,037 $637,000
Q3 2022

Nov 03, 2022

BUY
$31.52 - $373.61 $387,822 - $4.6 Million
12,304 New
12,304 $395,000
Q1 2021

Apr 30, 2021

SELL
$30.92 - $44.4 $158,372 - $227,416
-5,122 Closed
0 $0
Q4 2020

Jan 29, 2021

SELL
$33.66 - $40.76 $1.58 Million - $1.91 Million
-46,813 Reduced 90.14%
5,122 $208,000
Q3 2020

Nov 05, 2020

BUY
$33.07 - $38.68 $7,407 - $8,664
224 Added 0.43%
51,935 $1.9 Million
Q2 2020

Jul 23, 2020

BUY
$20.05 - $33.89 $1.04 Million - $1.75 Million
51,711 New
51,711 $1.75 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $14.1B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.